TEVA.N Relative Valuation
TEVA.N's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TEVA.N is overvalued; if below, it's undervalued.
Historical Valuation
Teva Pharmaceutical Industries Ltd (TEVA.N) is now in the Overvalued zone, suggesting that its current forward PE ratio of 11.16 is considered Overvalued compared with the five-year average of 4.69. The fair price of Teva Pharmaceutical Industries Ltd (TEVA.N) is between 12.55 to 19.69 according to relative valuation methord. Compared to the current price of 28.46 USD , Teva Pharmaceutical Industries Ltd is Overvalued By 44.53%.
Relative Value
Fair Zone
12.55-19.69
Current Price：28.46
44.53%
Overvalued
11.16
PE
1Y
3Y
5Y
Trailing
Forward
9.52
EV/EBITDA
Teva Pharmaceutical Industries Ltd. (TEVA.N) has a current EV/EBITDA of 9.52. The 5-year average EV/EBITDA is 6.93. The thresholds are as follows: Strongly Undervalued below 5.80, Undervalued between 5.80 and 6.37, Fairly Valued between 7.50 and 6.37, Overvalued between 7.50 and 8.06, and Strongly Overvalued above 8.06. The current Forward EV/EBITDA of 9.52 falls within the Strongly Overvalued range.
10.54
EV/EBIT
Teva Pharmaceutical Industries Ltd. (TEVA.N) has a current EV/EBIT of 10.54. The 5-year average EV/EBIT is 7.80. The thresholds are as follows: Strongly Undervalued below 6.53, Undervalued between 6.53 and 7.17, Fairly Valued between 8.44 and 7.17, Overvalued between 8.44 and 9.07, and Strongly Overvalued above 9.07. The current Forward EV/EBIT of 10.54 falls within the Strongly Overvalued range.
1.93
PS
Teva Pharmaceutical Industries Ltd. (TEVA.N) has a current PS of 1.93. The 5-year average PS is 0.86. The thresholds are as follows: Strongly Undervalued below 0.29, Undervalued between 0.29 and 0.57, Fairly Valued between 1.14 and 0.57, Overvalued between 1.14 and 1.43, and Strongly Overvalued above 1.43. The current Forward PS of 1.93 falls within the Strongly Overvalued range.
8.55
P/OCF
Teva Pharmaceutical Industries Ltd. (TEVA.N) has a current P/OCF of 8.55. The 5-year average P/OCF is 11.71. The thresholds are as follows: Strongly Undervalued below -11.03, Undervalued between -11.03 and 0.34, Fairly Valued between 23.09 and 0.34, Overvalued between 23.09 and 34.46, and Strongly Overvalued above 34.46. The current Forward P/OCF of 8.55 falls within the Historic Trend Line -Fairly Valued range.
9.67
P/FCF
Teva Pharmaceutical Industries Ltd. (TEVA.N) has a current P/FCF of 9.67. The 5-year average P/FCF is 5.81. The thresholds are as follows: Strongly Undervalued below 1.45, Undervalued between 1.45 and 3.63, Fairly Valued between 7.99 and 3.63, Overvalued between 7.99 and 10.17, and Strongly Overvalued above 10.17. The current Forward P/FCF of 9.67 falls within the Overvalued range.
Teva Pharmaceutical Industries Ltd (TEVA.N) has a current Price-to-Book (P/B) ratio of 4.50. Compared to its 3-year average P/B ratio of 2.41 , the current P/B ratio is approximately 87.26% higher. Relative to its 5-year average P/B ratio of 1.86, the current P/B ratio is about 141.84% higher. Teva Pharmaceutical Industries Ltd (TEVA.N) has a Forward Free Cash Flow (FCF) yield of approximately 1.77%. Compared to its 3-year average FCF yield of 6.12%, the current FCF yield is approximately -71.10% lower. Relative to its 5-year average FCF yield of 4.84% , the current FCF yield is about -63.41% lower.
4.50
P/B
Median3y
2.41
Median5y
1.86
1.77
FCF Yield
Median3y
6.12
Median5y
4.84
Competitors Valuation Multiple
The average P/S ratio for TEVA.N's competitors is 1.93, providing a benchmark for relative valuation. Teva Pharmaceutical Industries Ltd Corp (TEVA.N) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TEVA.N increased by 29.13% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 13.83 to 46.12.
The secondary factor is the Revenue Growth, contributed 3.42%to the performance.
Overall, the performance of TEVA.N in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Teva Pharmaceutical Industries Ltd (TEVA.N) currently overvalued or undervalued?
What is Teva Pharmaceutical Industries Ltd (TEVA.N) fair value?
How does TEVA.N's valuation metrics compare to the industry average?
What is the current P/B ratio for Teva Pharmaceutical Industries Ltd (TEVA.N) as of Dec 07 2025?
What is the current FCF Yield for Teva Pharmaceutical Industries Ltd (TEVA.N) as of Dec 07 2025?
What is the current Forward P/E ratio for Teva Pharmaceutical Industries Ltd (TEVA.N) as of Dec 07 2025?